, /PRNewswire/ -- Berger Montague，一家全国性的证券诉讼律师事务所，向 Hims &amp; Hers Health Inc.（&#34;Hims &amp; Hers&#34;或&#34;公司&#34;）（NYSE: HIMS）的股东通报，关于对 Hims &amp; Hers 董事会的调查，涉及其在与 Novo Nordisk A/S 终止合作关系时可能违反对公司及其股东的信托责任。
HIMS &amp; HERS 的股东可以通过联系 Berger Montague 了解更多关于此调查的信息：Radha Raghavan，电子邮件 [email protected] 或电话 (332) 271-8908，或 Andrew Abramowitz，电子邮件 [email protected] 或电话 (215) 875-3015，或通过点击此处 .
Berger Montague 的调查重点是 Hims &amp; Hers 董事会在监督公司与 Novo Nordisk 的合作关系时是否违反了其信托责任，包括与 Novo Nordisk 在 2025 年 6 月宣布终止与 Hims &amp; Hers 的合作关系有关，理由是公司在未获批准的复合版本 semaglutide 的营销中存在欺骗性行为。
Berger Montague 自 1970 年成立以来，一直是证券集体诉讼的先驱，拥有位于费城、明尼阿波利斯、特拉华州、华盛顿特区、圣地亚哥、旧金山、芝加哥、马尔文（宾夕法尼亚州）和多伦多的办事处。Berger Montague 在过去五十多年中代表个人和机构投资者，并在美国各地的法院担任首席律师。
联系方式：
Radha Raghavan，助理
Berger Montague
(332) 271-8908
[email protected]
Andrew Abramowitz，高级顾问
Berger Montague
(215) 875-3015
[email protected]
来源：Berger Montague
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDAzJk5ld3NJdGVtSWQ9REM5MDAzMiZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMDMxMTM3UFJfTkVXU19VU1BSX19fX19EQzkwMDMy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDAzJk5ld3NJdGVtSWQ9REM5MDAzMiZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMDMxMTM3UFJfTkVXU19VU1BSX19fX19EQzkwMDMy"/>

HIMS

Berger Montague 正在调查 Hims & Hers Health Inc.（纽约证券交易所代码：HIMS）董事会可能存在的信托责任违规行为。这项调查是在诺和诺德（Novo Nordisk A/S）终止与 Hims & Hers 的合作关系后进行的，原因是其涉及与未经批准的复合版本 semaglutide 相关的欺骗性营销行为。股东可以联系 Berger Montague 以获取有关调查的更多信息

, /PRNewswire/ -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims &amp; Hers Health Inc. (&#34;Hims &amp; Hers&#34; or the &#34;Company&#34;) ( NYSE: HIMS) about an investigation into Hims &amp; Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims &amp; Hers.
<div class="lb-trans">, /PRNewswire/ -- Berger Montague，一家全国性的证券诉讼律师事务所，向 Hims &amp; Hers Health Inc.（&#34;Hims &amp; Hers&#34;或&#34;公司&#34;）（NYSE: HIMS）的股东通报，关于对 Hims &amp; Hers 董事会的调查，涉及其在与 Novo Nordisk A/S 终止合作关系时可能违反对公司及其股东的信托责任。
</div>Shareholders of HIMS &amp; HERS may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) 875-3015 or by CLICKING HERE .
<div class="lb-trans">HIMS &amp; HERS 的股东可以通过联系 Berger Montague 了解更多关于此调查的信息：Radha Raghavan，电子邮件 [email protected] 或电话 (332) 271-8908，或 Andrew Abramowitz，电子邮件 [email protected] 或电话 (215) 875-3015，或通过点击此处 .
</div>Berger Montague's investigation is focused on whether Hims &amp; Hers' Board of Directors breached its fiduciary duties in the manner in which it oversaw the Company's partnership with Novo Nordisk, including in connection with Novo Nordisk's announcement in June 2025 that it was terminating its partnership with Hims &amp; Hers on the basis that the Company had engaged in deceptive marketing practices with respect to unapproved compounded versions of semaglutide.
<div class="lb-trans">Berger Montague 的调查重点是 Hims &amp; Hers 董事会在监督公司与 Novo Nordisk 的合作关系时是否违反了其信托责任，包括与 Novo Nordisk 在 2025 年 6 月宣布终止与 Hims &amp; Hers 的合作关系有关，理由是公司在未获批准的复合版本 semaglutide 的营销中存在欺骗性行为。
</div>Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
<div class="lb-trans">Berger Montague 自 1970 年成立以来，一直是证券集体诉讼的先驱，拥有位于费城、明尼阿波利斯、特拉华州、华盛顿特区、圣地亚哥、旧金山、芝加哥、马尔文（宾夕法尼亚州）和多伦多的办事处。Berger Montague 在过去五十多年中代表个人和机构投资者，并在美国各地的法院担任首席律师。
</div>Contacts:
<div class="lb-trans">联系方式：
</div>Radha Raghavan, Associate
<div class="lb-trans">Radha Raghavan，助理
</div>Berger Montague
<div class="lb-trans">Berger Montague
</div>(332) 271-8908
<div class="lb-trans">(332) 271-8908
</div>[email protected]
<div class="lb-trans">[email protected]
</div>Andrew Abramowitz, Senior Counsel
<div class="lb-trans">Andrew Abramowitz，高级顾问
</div>Berger Montague
<div class="lb-trans">Berger Montague
</div>(215) 875-3015
<div class="lb-trans">(215) 875-3015
</div>[email protected]
<div class="lb-trans">[email protected]
</div>SOURCE Berger Montague
<div class="lb-trans">来源：Berger Montague
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDAzJk5ld3NJdGVtSWQ9REM5MDAzMiZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMDMxMTM3UFJfTkVXU19VU1BSX19fX19EQzkwMDMy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC90032&amp;Transmission_Id=202510031137PR_NEWS_USPR_____DC90032&amp;DateId=20251003"/>

Berger Montague 正在调查 Hims & Hers Health Inc.（NYSE: HIMS）董事会是否存在潜在的信托责任违约行为